Table D-36. Evidence table for studies addressing management of PPH (Kayem 2011a)

| **Study** **Description** | **Intervention** | **Inclusion/Exclusion** **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| Author:Kayem et al., 201140Country: UKEnrollment period: September 2007 to March 2009Birth setting: Consultant-led maternity units Facility characteristics: NRFunding:Wellbeing of Women. AXA Research Fund.National Coordinating Centre for Research Capacity Development of the National Institute for HealthResearch.Policy Research Programmein the Department of Health part funded UKOSS (Independent study from which this paper reports)Design: Prospective cohort studyNote: See related study, Kayem 201141 | **Intervention:** Uterine compression suturesPelvic vessel ligationInterventional radiological techniques Recombinant factor VIIa (rFVIIa)**Groups:****G1:** Uterine compression sutures**G2:** Pelvic vessel ligation**G3:** Interventional radiological techniques**G4:** Recombinant factor VIIa (rFVIIa)**N at enrollment:** **G1:** 199**G2:** 20**G3:** 22**G4:** 31N at follow-up: NRDuration of treatment: NRTiming of treatment : NROrder of treatment: NRLength of follow-up: NRPrimary treatment of women managed with different second-line therapies, n (%):Uterotonic prophylaxis G1: 195 (98) G2: 20 (100) G3: 22 (100) G4: 30 (97)Primary uterotonic treatments:Oxytocin G1: 195 (98) G2: 16 (80) G3: 18 (82) G4: 28 (90)Ergometrine G1: 106 (53) G2: 6 (30) G3: 6 (27) G4: 11 (35)Misoprostol G1: 127 (64) G2: 8 (40) G3: 9 (41) G4: 18 (58)Carboprost G1: 142 (71) G2: 12 (60) G3: 11 (50) G4: 17 (55)Uterine balloon or packingbefore second-line therapyprocedureG1: 38 (19) G2: 6 (30) G3: 8 (36) G4: 15 (48) | **Operational definition of PPH:** NR**Definition of success of treatment**: No requirement for either a further therapy totreat PPH or hysterectomy **Method of blood loss measurement:** NR**Severity:** NRInclusion criteria: * Woman giving birth and undergoing treatment

for PPH with the following procedures: uterine compression sutures, rFVIIa, interventional radiology including intra-arterial balloon occlusion and arterial embolization or pelvic vessel ligation during the study period.Exclusion criteria: * Women who had a PPH treated successfully by

intra-uterine balloon tamponade, and who were not managed with any of the other therapies**Maternal age, yrs, n (%):**<35**G1:** 128 (64) **G2:** 12 (60)**G3:** 12 (55)**G4:** 21 (68)≥35**G1:** 71 (36) **G2:** 8 (40) **G3:** 10 (45)**G4:** 10 (32)**Parity, n (%):** Nulliparous**G1:** 92 (46)**G2:** 3 (15)**G3:** 6 (27)**G4:** 9 (29)Multiparous **G1:** 107 (54)**G2:** 17 (85)**G3:** 16 (73) **G4:** 22 (71)**Weeks gestation:** NR**Single pregnancy:** NR**Multiple pregnancy, n (%):****G1:** 19 (10)**G2:** 1 (5)**G3:** 1 (5) **G4:** 0**Race/ethnicity:** NR**BMI** **(kg/m2), n (%):****<30****G1:** 149 (80) **G2:** 15 (79)**G3:** 12 (71)**G4:** 25 (89)**≥30****G1:** 37 (20) **G2:** 4 (21) **G3:** 5 (29) **G4:** 3 (11)**Baseline hemoglobin:** NR**SES:** NR**Mode of birth, n (%):** Vaginal birth**G1:** 17 (9) **G2:** 3 (15) **G3:** 7 (32) **G4:** 15 (48)Caesarean section during labour**G1:** 96 (48) **G2:** 5 (25) **G3:** 4 (18) **G4:** 5 (16)Caesarean section before labour**G1:** 86 (43) **G2:** 12 (60) **G3:** 11 (50) **G4:** 11 (35)**Risk factors, n (%):** History of cesarean:**G1:** 57 (29) **G2:** 9 (45) **G3:** 11 (50) **G4:** 11 (35)Previous uterine surgery:**G1:** 33 (17) **G2:** 4 (20) **G3:** 1 (5) **G4:** 5 (17)Placenta praevia diagnosedbefore labour: **G1:** 19 (10) **G2:** 4 (20) **G3:** 8 (36) **G4:** 6 (19)Placenta accreta suspectedbefore labour:**G1:** 3 (2) **G2:** 1 (5) **G3:** 4 (18) **G4:** 2 (6)Multiple gestation**G1:** 19 (10)**G2:** 1 (5)**G3:** 1 (5) **G4:** 0Induction of labour:Yes **G1:** 53 (27) **G2:** 1 (5) **G3:** 3 (14) **G4:** 13 (42)No **G1:** 146 (73) **G2:** 19 (95) **G3:** 19 (83) **G4:** 18 (58)Use of oxytocin during labour:Yes **G1:** 57 (51) **G2:** 2 (25) **G3:** 3 (27) **G4:** 8 (40)No **G1:** 54 (48) **G2:** 6 (75) **G3:** 8 (73) **G4:** 12 (60)**Primary etiology of PPH, n (%):** Atony**G1:** 126 (63) **G2:** 5 (25) **G3:** 2 (9) **G4:** 13 (42)Placenta accreta**G1:** 17 (9) **G2:** 1 (5) **G3:** 4 (18) **G4:** 4 (13)Placenta previa without accreta**G1:** 13 (7) **G2:** 4 (20) **G3:** 4 (18) **G4:** 3 (10)Uterine tear **G1:** 22 (11) **G2:** 6 (30) **G3:** 3 (14) **G4:** 3 (10)Other **G1:** 21 (11) **G2:** 4 (20) **G3:** 9 (41) **G4:** 8 (26)Disseminated intravascular coagulation**G1:** 24 (12) **G2:** 3 (15) **G3:** 3 (14) **G4:** 12 (39) | **Blood loss:** NR**Transfusion, n (%):**Red cells **G1:** 168 (87) **G2:** 19 (95) **G3:** 21 (95) **G4:** 30 (100)Fresh frozen plasma**G1:** 124 (66) **G2:** 17 (85) **G3:** 16 (73) **G4:** 30 (100)Platelets**G1:** 65 (35) **G2:** 13 (65) **G3:** 9 (41)**G4:** 24 (80)Cryoprecipitate **G1:** 47 (26) **G2:** 11 (55)**G3:** 6 (29) **G4:** 24 (80) **Success rates, n (%), 95% CI:**After Uterotonic only, n=205**G1:** 120 (75), 67-81**G2:** 5 (36), 13-65**G3:** 12 (86), 57-98**G4:** 5 (31), 11-59After failure of intrauterine tamponade, n=67**G1:** 20 (53), 36–69**G2:** 1 (17), 0–64**G3:** 7 (87), 47–100**G4:** 4 (27 ), 8–55**Additional treatment, n (%), 95% CI:**After Uterotonic only**G1:** 16 (10), 6–16**G2:** 7 (50), 23–77**G3:** 0 (0), 0–23**G4:** 4 (25), 7–52After failure of intrauterine tamponade**G1:** 10 (26), 13–43**G2:** 5 (83), 36–100**G3:** 1 (12), 0–53**G4:** 4 (27), 8–55**Uterine preservation, total n (%), 95% CI:**Hysterectomy after Uterotonic only**G1:** 32 (20), 14-27**G2:** 6 (43), 18-71**G3:** 2 (14), 0-43**G4:** 7(44), 20-70Hysterectomy after failure of intrauterine tamponade**G1:** 14 (37), 22–54**G2:** 3 (50), 12–88**G3:** 0 (0), 0–37**G4:** 7 (47), 21–73**ICU admission:** NR**Anemia:** NR **Length of stay:** NR**Mortality, total n:** 0**Future fertility:** NR **Breastfeeding:** NR**Psychological impact:** NR**Harms of intervention, total n:**Acute Respiratory Syndrome5Pulmonary oedema11Cardiac arrest5Other6**Confounders:** NR**Effect modifiers:** NR |